Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995625 | 0.92 | PIK3CD (0.66) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL993919 | 0.91 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL994262 | 0.88 | PIK3CD (0.66) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL993386 | 0.88 | PIK3CD (0.66) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL3621445 | 0.88 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL2465908 | 0.87 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL994907 | 0.87 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL13640222 | 0.86 | PIK3CD (0.70) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL3624204 | 0.85 | PIK3CD (0.68) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL12926419 | 0.85 | PIK3CD (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | claimed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | claimed |
| EP-2205610-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | claimed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | claimed |
| EP-2205610-B1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2205610-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.